e-Drug3D

1581

LINACLOTIDE

INN
LINACLOTIDE

(has an active metabolite)

cas 851199-59-2

CLASS

METABOLISM
GUANYLATE CYCLASE-C AGONIST
IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
CHRONIC IDIOPATHIC CONSTIPATION

ROUTE (list)

ORAL

ATC code

A06AX04

PK parameters

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET GUANYLATE CYCLASE-C (GC-C)

DrugCentral

Heat-stable enterotoxin receptor UNIPROT P25092 GUCY2C

Download SDF file

L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (1->6),(2->10),(5->13)-tris(disulfide)

Formula:
C59H79N15O21S6

Calculated chemical properties:

MW 1524.78
NB_atoms 101
XLogP -8.61
PSA 532.29
NB_HD 19
NB_HA 36
fsp3 0.53
Lipinski(0=no;1=yes) 0

FDA
NDA 202811 (label) INN (LINACLOTIDE) LINZESS (ABBVIE) APPROVAL= AP YEAR= 2012
NDA 209564 (pdf not found) INN (LINACLOTIDE) LINACLOTIDE (MYLAN) APPROVAL= AP YEAR= 2021 DISCONTINUED
NDA 211255 (pdf not found) INN (LINACLOTIDE) LINACLOTIDE (ACTAVIS LABS FL INC) APPROVAL= TA YEAR= 2022
NDA 209611 (pdf not found) INN (LINACLOTIDE) LINACLOTIDE (AUROBINDO PHARMA) APPROVAL= AP YEAR= 2023 DISCONTINUED